Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588309 | 0.88 | CETP (0.44) | CETPPSEN1ALOX5PPARGPTGES | |
| SCHEMBL4499649 | 0.88 | CETP (0.42) | CETPCYSLTR2CYSLTR1PDK2GPBAR1 | |
| SCHEMBL4495620 | 0.82 | CETP (0.40) | CETPGPBAR1 | |
| SCHEMBL4506280 | 0.82 | CETP (0.47) | CETPPDK2 | |
| SCHEMBL129291 | 0.80 | PDK2 (0.41) | CETPCYSLTR2CYSLTR1PDK2GPBAR1 | |
| SCHEMBL2082005 | 0.79 | CETP (0.41) | CETPPPARGPDK2GPBAR1DHFR | |
| SCHEMBL1587666 | 0.79 | GPBAR1 (0.47) | CETPPDK2GPBAR1DHFR | |
| SCHEMBL5071423 | 0.78 | CETP (0.44) | CETPPSEN1ALOX5PPARGPTGES | |
| SCHEMBL130695 | 0.78 | CETP (0.41) | CETPPDK2GPBAR1 | |
| SCHEMBL130591 | 0.78 | CETP (0.42) | CETPPPARGPDK2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885PSEN1 2699/4885ALOX5 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.